{"id":"dapagliflozin-sitagliptin","safety":{"commonSideEffects":[{"rate":"5–10","effect":"Genital mycotic infections"},{"rate":"5–8","effect":"Nasopharyngitis"},{"rate":"3–5","effect":"Urinary tract infection"},{"rate":"2–5","effect":"Hypoglycemia"},{"rate":"2–4","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL429910","moleculeType":"Small molecule","molecularWeight":"408.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapagliflozin is an SGLT2 inhibitor that blocks reabsorption of glucose in the kidney, promoting glucose excretion in urine. Sitagliptin is a DPP-4 inhibitor that prevents degradation of incretin hormones (GLP-1 and GIP), thereby enhancing insulin secretion and reducing glucagon in response to meals. Together, they provide complementary glucose-lowering effects through distinct mechanisms.","oneSentence":"This combination drug lowers blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and inhibiting DPP-4 to increase incretin levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:02.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05042505","phase":"NA","title":"Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Liver Transplant; Complications","enrollment":100},{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT06263673","phase":"PHASE4","title":"Anti-Diabetic Medications to Fight PD and LBD","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-05-07","conditions":"Lewy Body Dementia, Parkinson Disease","enrollment":18},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT07108985","phase":"PHASE4","title":"Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-09","conditions":"Diabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance","enrollment":100},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT05833958","phase":"PHASE2","title":"Polypill Versus Metformin in New Onset Type 2 Diabetes","status":"WITHDRAWN","sponsor":"George Medicines PTY Limited","startDate":"2024-09","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT03939624","phase":"","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Type2 Diabetes, Myocardial Infarction, Ischemic Stroke","enrollment":419734},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT06147518","phase":"NA","title":"To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-12-20","conditions":"Compensated Cirrhosis, Decompensated Cirrhosis","enrollment":240},{"nctId":"NCT06148259","phase":"NA","title":"SGLT Inhibitors Versus DDP4 Inhibitors and Prostate in Patient With Diabetes","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2021-03-12","conditions":"Diabetes Mellitus, Prostatic Hyperplasia","enrollment":57},{"nctId":"NCT04882813","phase":"","title":"Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-12-13","conditions":"Chronic Kidney Disease","enrollment":87727},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05453786","phase":"PHASE1","title":"A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2022-06-23","conditions":"Healthy Subjects","enrollment":51},{"nctId":"NCT05236998","phase":"PHASE1","title":"A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2021-11-03","conditions":"Healthy Subjects","enrollment":45},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT05266404","phase":"PHASE1","title":"Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-21","conditions":"Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)","enrollment":46},{"nctId":"NCT05403281","phase":"PHASE1","title":"A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2021-11-05","conditions":"Healthy Subjects","enrollment":41},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT03959501","phase":"PHASE4","title":"Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2017-08-16","conditions":"Type 2 Diabetes, Ketonemia","enrollment":60},{"nctId":"NCT04287387","phase":"PHASE4","title":"Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-02","conditions":"Type2 Diabetes Mellitus","enrollment":180},{"nctId":"NCT03804411","phase":"PHASE4","title":"Prognostic Predictors of Response to Hypoglycemic Therapy","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2017-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":800},{"nctId":"NCT04149067","phase":"","title":"Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2017-06-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1080},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT02610088","phase":"PHASE4","title":"Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-11","conditions":"Diabetes","enrollment":32},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT03078049","phase":"","title":"Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-31","conditions":"Diabetes Mellitus Type 2","enrollment":11971},{"nctId":"NCT02946632","phase":"PHASE3","title":"Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2016-12","conditions":"Diabetes Mellitus, Type II","enrollment":104},{"nctId":"NCT00842556","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":5000},{"nctId":"NCT02528019","phase":"PHASE4","title":"Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors","status":"UNKNOWN","sponsor":"Kurume University","startDate":"2015-08","conditions":"Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications","enrollment":100},{"nctId":"NCT00984867","phase":"PHASE3","title":"Dapagliflozin DPPIV Inhibitor add-on Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes","enrollment":833},{"nctId":"NCT00855166","phase":"PHASE3","title":"Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus","enrollment":182}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dapagliflozin/Sitagliptin","genericName":"Dapagliflozin/Sitagliptin","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug lowers blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and inhibiting DPP-4 to increase incretin levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}